Original Article
Prostate Cancer and Prostatic Diseases (2009) 12, 41–46; doi:10.1038/pcan.2008.33; published online 3 June 2008
Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts
K Welén1, K Jennbacken1, T Te
an1 and J-E Damber1
1Department of Urology, Lundberg Laboratory for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Correspondence: Dr K Welén, Department of Urology, Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Gula stråket 8, 413 45 Göteborg, Sweden. E-mail: karin.welen@urology.gu.se
Received 19 March 2008; Accepted 11 April 2008; Published online 3 June 2008.
Abstract
Androgen-independent prostate cancer is an aggressive disease with high angiogenic and metastatic potential. Increased microvessel density and altered invasion properties have previously been described in LNCaP-19, an androgen-independent subline to LNCaP. To characterize the differences in angiogenesis and invasion, the vessels of these tumour xenografts were investigated with immunohistochemistry, and the influence of tumour cells on endothelial cell migration, proliferation and tube formation was studied in vitro. The blood vessels of LNCaP were found to be stabilized by pericytes more frequently than vessels in LNCaP-19. Further, tumour cell invasion was decreased in pericyte-covered blood vessels in both the tumour types. LNCaP-19 displayed an increased potential to induce endothelial cell migration in vitro. In conclusion, pericyte coverage seems to be important for the invasion of tumour cells into blood vessels. Further, LNCaP-19 has lower pericyte coverage and an increased potential to induce endothelial cell migration, which reflects its high microvessel density.
Keywords:
hormone refractory, angiogenesis, pericyte, invasion, migration
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Prostate Cancer and Prostatic Diseases Review
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B
Oncogene Original Article
Molecular Therapy Original Article
Laboratory Investigation Article Response
The EMBO Journal Article (15 Aug 2003)
